Sangamo Therapeutics Inc (SGMO) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.01 or -0.91% from the prior close of $1.1. The stock opened at $1.1 and touched a low of ...

NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...

NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...

We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this article, we are going to take a look at where Sangamo Therapeutics Inc. (NASDAQ:SGMO) stands against the ...

Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended its program.

NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a biotechnology company specializing in genomic medicine and gene therapies, stands at a critical juncture as it navigates a complex landscape of clinical ...

Shares of Sangamo Therapeutics have plummeted more than 56% over the past few days after Pfizer announced it had terminated its partnership to develop an investigational gene therapy product to treat ...